|Position||Trades||Duration||Win rate||Win/loss||Avg win||Avg loss||Return|
|Position||Trades||Duration||Win Rate||Win/Loss||Avg Win||Avg Loss||Return|
CHAIKIN MONEY FLOW
Trading: HOLD @ $44.18
Signal Strength: MEDIUM
Chemocentryx (NASDAQ:CCXI) current price has highlighted recent buying pressure and the continuation of a bullish trading conditions. Currently, the CMF is 0.11. CCXI received a confirmed CMF crossover days on the Dec 27 2019. The bullish signal has been active for 0 day. During the quarter, the highest CMF value was 0.36 occurring on the Dec 27 2019.
Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading entry. Indicator can be applied to the short/medium term timeframe, but the best results are obtained with larger cyclical swings in-line with the trend direction. This accumulation / distribution oscillator can provide guidance on the money flow direction from the companies recent trading.
Developed by Marc Chaikin, Chaikin Money Flow measures the amount of Money Flow Volume over a specific period. Money Flow Volume forms the basis for the Accumulation Distribution Line. Instead of a cumulative total of Money Flow Volume, Chaikin Money Flow simply sums Money Flow Volume for a specific look-back period, typically 20 or 21 days. The resulting indicator fluctuates above/below the zero line just like an oscillator. Chartists weigh the balance of buying or selling pressure with the absolute level of Chaikin Money Flow. Chartists can also look for crosses above or below the zero line to identify changes on money flow.
Calculation: Chaikin Money Flow (20):
1) Money Flow Multiplier = [(Close - Low) - (High - Close)] / (High - Low);
2) Money Flow Volume = Money Flow Multiplier x Volume for the Period;
3) 20-period CMF = 20-period Sum of Money Flow Volume / 20 period Sum of Volume;
PROFILE: Chemocentryx (CCXI)
Stock Exchange: NASDAQ
Ticker Codes: | CCXI | NASDAQ:CCXI |
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). The company is also developing Avacopan for the treatment of patients with C3 glomerulopathy (C3G), hidradenitis suppurativa (HS), and in atypical hemolytic uremic syndrome (aHUS). In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy (DN) and is being developed for patients with focal segmental glomerulosclerosis (FSGS). Further, it has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases, and in cancer. The company was founded in 1997 and is headquartered in Mountain View, California.
|STKL Sunopta Inc||2.69||13||767,118||-0.04||BEARISH|
|ECPG Encore Capital||34.61||12||1,185,057||-0.1||BEARISH|
|BCRX BioCryst Pharmaceuticals||2.74||8.3||11,180,169||-0.34||BEARISH|
|CRIS Curis Inc||1.23||7||256,944||-0.09||BEARISH|
|DLTH Duluth Holdings||7.39||5.1||226,062||-0.02||BEARISH|
|PME Pingtan Marine||1.26||5||12,660||-0.12||BEARISH|
|PACB Pacific Biosciences||3.52||4.1||3,526,846||-0.08||BEARISH|
|CLDX Celldex Therapeutics||2.71||3.8||455,237||-0.14||BEARISH|
|FRGI Fiesta Restaurant||9.44||3.7||499,690||-0.06||BEARISH|